ABSTRACT Some trials administered antituberculosis agents for 5 of 7 days (5/7-day regimen) to optimize adherence. Since moxifloxacin has a longer half-life than rifampin, rifampin concentrations are <1% of the maximum concentration in serum (C max ) on day 6 and nondetectable on day 7, while concentrations of moxifloxacin remain and are able to induce error-prone replication. We determined if functional moxifloxacin monotherapy for 24 h/week caused resistance. In in vitro pharmacodynamic experiments, Mycobacterium tuberculosis was treated with mean area under the concentration-time curve (AUC) exposures for moxifloxacin and rifampin of 400 and 600 mg/kg/day and exposures equal to 1 standard deviation (SD) above and below the mean values. The drugs were administered on schedules of 7/7 days and 5/7 days. Over the 28-day experiments, bacteria were plated onto antibiotic-free agar to determine the effects of exposure and schedule on the total population. MICs were checked for emergence of resistance. At days 7 and 14, there was a 0.56-to 1.22-log 10 -CFU/ml greater cell kill with the 7/7-day regimen versus the 5/7-day regimen (low exposure). This difference was not seen for the larger exposures at day 21. At day 23, the low-exposure 5/7-day arm had breakthrough resistance, with the total count increasing to >2 log 10 CFU/ml above the low-exposure 7/7-day arm. Pharmacokinetic mismatching of drugs in the therapy of tuberculosis may result in emergence of resistance when a drug holiday is imposed during which there is functional monotherapy and where the remaining agent induces error-prone replication. This is particularly true for the portion of the population where the clearance is higher (1 SD above the mean).
number of clinical and preclinical studies have administered therapy for Mycobacterium tuberculosis on a schedule of 5 days out of 7 days (5/7-day regimen), with the idea that this would improve regimen adherence. Most recently, these trials have included moxifloxacin and rifampin as part of the therapy (1, 2) . Moxifloxacin and rifampin have somewhat discordant serum half-lives, and they have been demonstrated by Weiner et al. (3) to interact, causing moxifloxacin clearance to increase (and the moxifloxacin area under the concentration-time curve [AUC] to decrease) by 27% when administered in the presence of rifampin.
The discordance in serum half-lives of moxifloxacin and rifampin may have important implications. Over the 48 h in which both drugs are not administered, the concentration of rifampin will be less than 1% of the peak concentration at the end of the first day and undetectable on the second day, while moxifloxacin still retains considerable concentrations during this period because of its longer half-life. Furthermore, as a fluoroquinolone, moxifloxacin induces error-prone replication in M. tuberculosis (4) . Consequently, it is reasonable to hypothesize that the discordance in half-lives may lead to emergence of resistance to one or both drugs. We decided to test this hypothesis with our hollow fiber infection model (HFIM) (Fig. 1) . We compared the impacts of drug exposures on 7/7-day and a 5/7-day dosing schedules on breakthrough regrowth over 28 days and assessed whether regrowth was due to emergence of resistance to either moxifloxacin (expected) or rifampin. The ability to suppress resistance with combination chemotherapy is a key factor in the ultimate outcome of therapy for M. tuberculosis.
RESULTS
Organism rifampin and moxifloxacin MICs and mutation frequencies. For M. tuberculosis strain H37Ra, the MIC for rifampin was 0.06 mg/liter and the mutation frequency to 2.0 mg/liter of rifampin was 1/6.921 log 10 CFU. For moxifloxacin, the MIC was 0.25 mg/liter and the mutation frequency to resistance to 1.0 mg/ liter was 1/6.524 log 10 CFU.
M. tuberculosis cell kill for different drug exposures and schedules of administration. Examination of the top panel of Fig. 2A demonstrates that the administration of moxifloxacin plus rifampin provided excellent cell kill over time when the drugs were administered 7/7 days. The relatively small free 24-h AUC (AUC 24 h ) exposure range examined did not result in a reliable exposure response for the organism kill. At day 28, the cell kill results for all three regimens (mean AUC for both drugs from the paper by Weiner [3] Ϯ 1 standard deviation [SD]) for this group were essentially identical. This was recapitulated in the second independent experiment (top panel of Fig. 2B ).
Importantly, in the groups treated 5/7 days with moxifloxacin and rifampin, there was a general trend for the cell kill to be less than that in the group treated 7/7 days, but the antimicrobial effect was not statistically different until after day 21. At this juncture, there was clear discordance among the regimens. The highestexposure regimens performed nearly identically at both 5/7 days and 7/7 days (top and bottom panels of Fig. 2A for the first experiment and top and bottom panels of Fig. 2B for the second experiment). However, in the lowest-exposure groups of the two administration schedules, there was a 2.25-to 2.5-log 10 -CFU/ml difference between the 7/7-day treatment group and the 5/7-day group in both experimental trials (top versus bottom panels of Fig. 2A and B) .
The ultimate difference, which largely explains the cell kill differences in the two schedules of administration, comes from the identification of emergence of resisitance in both performances of the experiment, solely in the low-exposure group in the 5/7-day administration schedule. The MIC for moxifloxacin increased from 0.25 mg/liter to 1.0 mg/liter, while the MIC for rifampin remained wild type.
Attainment of nominal concentration-time profiles. The simulated pharmacokinetic (PK) profiles for the first 72 h of the critical contrast arms (Fig. 3A, arm B-success versus arm Efailure) are displayed. The achieved drug concentrations for both agents were well matched between arms, indicating the difference in outcome is not attributable to difference in drug exposure, at least on a daily basis. For the other arms, the data indicate that the actual concentrations achieved were within approximately 10% of nominal. This was also true of the parallel experiment. For the lowest-exposure groups, the free AUC 0-168 h values for moxifloxacin were 68.9 mg·h/liter for the 7/7-day schedule and 50.86 mg·h/liter for the 5/7-day group. For rifampin, the free AUC 0-168 h values were 29.47 mg·h/liter and 22.12 mg·h/liter, respectively. On a per-day basis, the 5/7-day schedule group was marginally higher than the 7/7-day schedule group for both drugs (i.e., weekly exposure AUC 0-168 h values divided by 7 and 5, respectively).
DISCUSSION
In the therapy of tuberculosis, maintenance of drug susceptibility is critical. Emergence of resistance has two main roots. The first is inadequate drug therapy. Getting the dose wrong may have consequences for rapid emergence of resistance, even in the combination chemotherapy setting. The second is regimen adherence. It may be argued that adherence is at least as important as drug regimen and perhaps may be a more important cause of emergence of resistance.
In order to minimize regimen nonadherence, directly observed therapy was instituted for use with treatment that includes the standard first-line antituberculosis drugs (rifampin, isoniazid, and pyrazinamide). Because of the practical difficulty of seeing each patient on 7/7 days, regimens have been designed with short drug holidays which, given the relatively long turnover half-time of M. tuberculosis (circa 20 h), should result in minimal regrowth over the standard gap of 2 days.
We felt that the combination of moxifloxacin plus rifampin might be a special case with regard to emergence of resistance, because the serum half-lives of the drugs that are active against M. tuberculosis in log-phase growth are mismatched. Weiner et al. (3) found that there was drug interaction in volunteers, such that at 2 weeks, the half-life of moxifloxacin of 10.4 Ϯ 2.0 h when administered alone decreased to 6.5 Ϯ 0.9 h when moxifloxacin was administered in combination with rifampin. Rifampin, studied only in combination, had a half-life of 1.9 Ϯ 0.3 h. For a no-drug period of 48 h, rifampin will be essentially gone within the first 24 h (Ͼ12 terminal half-lives), while there will still be some moxi- We employed exposures at the mean of the free AUC 24 h for moxifloxacin and rifampin (3) as well as the free AUC 24 hs that were 1 SD above and below the mean exposure. Our previous publication examining this combination (5) demonstrated that, when administered on a daily basis, even small exposures to rifampin in combination with moxifloxacin still suppressed resistance.
We performed the experiment completely independently with two different teams at the same time. Examination of the top panels of Fig. 2A and B shows that, when administered 7/7 days, there was little evidence of an exposure response, and at day 28, there was no emergence of resistance.
In contrast, using the 5/7-day schedule, there was a divergence in the colony counts that became manifest after day 23 in both experiments, with a 2.25-to 2.5-log 10 -CFU/ml increase in colony counts when contrasting the lowest exposure arms of the 7/7-and 5/7-day experiments (arm B versus arm E in Fig. 2A and B) . More importantly, the low-exposure arm (arm E) allowed emergence of resistance for moxifloxacin (4-fold increase in baseline MIC) in both experiments. It is important to note that in a normal distribution, 15.8% of the total population will have an AUC value at or below the value of the mean Ϫ 1 SD. This places a considerable fraction of the population at risk in this circumstance.
In conclusion, the results were able to be replicated, and in both instances, resistance emerged in the lowest-exposure arms, but not in the two higher-exposure arms when the drugs were administered 5/7 days. Administration of moxifloxacin and rifampin on a 7/7-day schedule suppressed resistance, even at the lowest exposure. This is concordant with our earlier publication (6) . The emergence of resistance explained the increase in colony counts in the low-exposure arms in the 5/7-day administration schedule relative to the 7/7-day schedule (increase of 2.25 to 2.5 log 10 CFU/ml in arm B versus arm E). The outcomes were not due to differences in achieved drug concentrations. Resistance occurred only to moxifloxacin.
When holiday schedules are designed to enhance regimen adherence, attention should be paid to whether or not error-prone replication is induced by one of the drugs, and there should be no discordance in the PK profiles so that both drugs are concurrently available to help suppress resistance. In the case of moxifloxacin   FIG 2 (A) First trial of moxifloxacin-plus-rifampin 7/7-day versus 5/7-day regimens. The AUC exposures in the symbol keys are the free AUC 24 hs that were infused into that particular hollow fiber system experimental arm on the days that the drugs were administered. (B) Second trial of moxifloxacin-plus-rifampin 7/7-day versus 5/7-day regimens. The AUC exposures in the figure legends are the free AUC 24 hs that were infused into that particular hollow fiber system experimental arm on the days that the drugs were administered. There is re-growth between day 23 and day 28, specifically in the lowest exposure group (arm E) in the experimental arm where the drugs were administered 5/7days. There was a 2.25 Log 10 (CFU/ml) difference between arms B and E, attributable to difference in administration schedule and weekly drug exposures. In arm E colonies recovered had a wild-type MIC for rifampin (0.03 mg/L), but increased 4-fold for moxifloxacin (0.25 to 1.0 mg/L). plus rifamycin, it may be that rifapentine may be a better choice if a 5/7-day administration schedule is to be contemplated since rifapentine has a serum half-life in humans of 13 h (5) compared with a 1.9-h serum half-life for rifampin.
MATERIALS AND METHODS
Bacterial isolate. M. tuberculosis H37Ra (ATCC 25177; American Type Culture Collection) was used in our studies. Bacterial cultures were stored at Ϫ80°C in Middlebrook 7H9 broth with 10% albumin-dextrosecatalase (ADC) and 0.025% Tween 80 (Becton Dickinson), and aliquots were thawed for study. The cultures were incubated in Middlebrook 7H9 broth with 10% ADC at 37°C with 5% CO 2 for 4 days to achieve exponential-phase growth.
Antimicrobial agents. Rifampin was obtained from Sigma-Aldrich, Inc. (St. Louis, MO). Stock solutions were prepared in dimethyl sulfoxide (DMSO), and aliquots were stored at -80°C. Moxifloxacin was purchased from CuraScript SD (Orlando, FL). Stock solutions of this antibiotic were prepared in sterile water, and aliquots were stored at -80°C. For each study, a sample of each drug was thawed, diluted to the desired concentration in sterile water or Middlebrook 7H9 broth with ADC, and used immediately. The concentration of DMSO that was infused into the hollow fiber systems with drug administration did not affect the growth of the bacterium.
MIC determination. The MICs for moxifloxacin and rifampin for the M. tuberculosis isolate were determined by plating 10 l of 1 ϫ 10 6 CFU/ml of log-phase-growth bacterium onto Middlebrook 7H10 plus 10% oleic acid, albumen, dextrose, and catalase (OADC) agar containing geometric 2-fold dilutions of rifampin or moxifloxacin. Plates were incubated at 37°C with 5% CO 2 in ambient air. The results were read after 21 days of incubation. The MIC was defined as the lowest concentration that allowed growth of M. tuberculosis of Յ1% compared with untreated controls.
Mutation frequency determinations. M. tuberculosis H37Ra was grown to exponential-phase growth in 7H9 broth plus ADC, as described above. On the fourth day, the mutation frequency (MF) in the cultures was determined by plating 5 ml of the bacterium onto plates containing Middlebrook 7H10 plus OADC containing either 32ϫ MIC of rifampin or 4ϫ MIC of moxifloxacin. The mutation frequency was determined after 21 days of incubation at 37°C with 5% CO 2 . This determination was performed aerobically.
Hollow fiber infection model. The hollow fiber infection model (HFIM) permits us to simulate the concentration-time profile for any dose of antibiotic (Fig. 1) . A computer-controlled syringe pump delivers the antibiotic into a central reservoir in the required amount at the desired schedule of administration. Fresh medium is pumped into the system while drug-containing medium is isovolumetrically removed from the system at rates programmed by the investigator to simulate the desired drug half-life.
In these experiments, 15 ml of M. tuberculosis H37Ra was inoculated into the peripheral compartments of hollow fiber cartridges at a concentration of 1 ϫ 10 6 to 5 ϫ 10 6 CFU/ml. Using human PK parameters from Weiner et al. (3) , the free-drug serum concentration-time profiles for moxifloxacin and rifampin were simulated. The free mean values of AUC of both agents were used, but also regimens with free AUC exposures that 
